Canada has added the UK to the list of countries that must be considered for the "timely submission requirement" in an application for a Certificate of Supplementary Protection (CSP). The change was implemented by an amendment to the CSP Regulations that came into force on January 6, 2021.

Impact on "timely submission requirement"

CSP eligibility is tied to both a patent and a medicinal ingredient contained in an approved drug. There are also certain timing requirements.

The "timely submission requirement" in paragraph 106(1)(f) of the Patent Act stipulates that the Canadian application for market authorization for the approved drug in question must have been filed within 12 months of the earliest market authorization application in certain prescribed countries.

The prescribed countries relevant to the "timely submission requirement" are set out in paragraph 6(1)(a) of the CSP Regulations. Prior to the January 6, 2021 amendment, the list of jurisdictions included the European Union and its member countries, along with the United States, Australia, Switzerland, and Japan. The list has now been amended to include the United Kingdom.

This amendment comes in response to the fact that the United Kingdom is no longer a member country of the European Union following Brexit.

Patentees are required to include an attestation that they have complied with the "timely submission requirement" as part of their CSP applications (see s. 8). The CSP application form and Guidance Document have now been amended to reflect this change.

CSP applicants should consult the applicable legislation and guidance documents for detailed information on CSP eligibility requirements, including details on complying with the "timely submission requirement".

Links to Health Canada Notice, Guidance Document, and updated CSP application form:


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.